KOWALSKI, JAMES,LAKSHMAN, JAY PARTHIBAN,PATEL, ARUN P.
申请号：
CA2552569
公开号：
CA2552569C
申请日:
2005.01.17
申请国别(地区):
CA
年份:
2012
代理人:
摘要：
Dipeptidylpeptidase IV inhibitor (herein referred to as DPP-IV) that may be98.5-100% pure is a high-dose drug capable of being directly compressed withspecific excipients into sold form dosage forms, such as tablets and capsuleshaving desired, hardness, disintegrating ability and acceptable dissolutioncharacteristics. DPP-IV is not inherently compressible and thus presentsformulation problems. Excipients used in the formulation enhance the flow andcompaction properties of the drug and tableting mix. Optimal flow contributesto uniform die fill and weight control. The binder used ensures sufficientcohesive properties that allow DPP-IV to be compressed using the directcompression method. The tablets produced provide an acceptable in vitrodissolution profile.
